Timp1 Antibody
- Known as:
- Timp1 Antibody
- Catalog number:
- csb-ma167191a0m
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- CusAb
- Gene target:
- Timp1 Antibody
Related genes to: Timp1 Antibody
- Gene:
- TIMP1 NIH gene
- Name:
- TIMP metallopeptidase inhibitor 1
- Previous symbol:
- TIMP, CLGI
- Synonyms:
- EPO
- Chromosome:
- Xp11.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2017-07-26
Related products to: Timp1 Antibody
Related articles to: Timp1 Antibody
- This study aimed to investigate the therapeutic effects of Bufei Nashen Pills(BFNSP) on chronic obstructive pulmonary disease(COPD), with a specific focus on whether it acted by modulating the balance between matrix metalloproteinases and tissue inhibitors of metalloproteinases(MMP/TIMP), which was mediated by the phosphatidylinositol 3-kinase/protein kinase B(PI3K/AKT) signaling pathway. The main components of BFNSP and its medicated serum were analyzed using liquid chromatography-mass spectrometry(LC-MS). A rat model of COPD was established by cigarette smoke exposure combined with lipopolysaccharide(LPS) injection, and the rats were subsequently treated with different doses of BFNSP. Lung function and histopathological changes in lung tissue were examined. The levels of inflammatory factors and extracellular matrix(ECM)-related indicators(such as MMP-9, MMP-3, TIMP-1, and hyaluronic acid(HA)) in bronchoalveolar lavage fluid(BALF) and serum were measured by enzyme-linked immunosorbent assay(ELISA). The expression of collagen Ⅰ, collagen Ⅲ, laminin, key molecules of the PI3K/AKT pathway, MMP-9, and TIMP-1 in lung tissues was detected using immunohistochemistry, reverse transcription-quantitative polymerase chain reaction(RT-qPCR), and Western blot. The research results showed that BFNSP effectively improved lung function, attenuated pathological injury, and reduced inflammatory response in COPD rats. More importantly, it significantly decreased the levels of MMP-9 and MMP-3, and increased the expression of TIMP-1 in both lung tissues and serum, thereby rectifying the MMP/TIMP imbalance and reducing the excessive deposition of ECM components, such as collagen. Mechanistic studies revealed that BFNSP inhibited the phosphorylation of PI3K and AKT in lung tissues. In summary, BFNSP may alleviate ECM deposition and retard the progression of COPD by suppressing the overactivation of the PI3K/AKT signaling pathway and consequently correcting the MMP/TIMP imbalance. - Source: PubMed
He Teng-FeiZhang An-NiZhang Chang-Xi - This study aimed to investigate the molecular mechanisms by which melatonin (MLT) mitigates ovarian damage in mice exposed to abnormal light cycles. Female C57BL/6 mice from the same batch were randomly assigned to five experimental groups: normal light cycle (LD), reversed light cycle (DL), reversed light cycle with MLT supplementation (MDL), constant light (LL), and constant light with MLT supplementation (MLL). Models of reversed and constant light exposure were established, and exogenous MLT was administered. The results indicated that MLT significantly alleviated ovarian developmental impairment induced by abnormal light cycles, reduced oocyte apoptosis, and attenuated the downregulation of Ddx4, androgen receptor (Ar), and estrogen receptor alpha (Erα) protein expression levels. RNA-seq analysis identified key genes involved in ovarian development, including Insl3, Runx2, and Timp1. Subsequent Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses revealed that differentially expressed genes were significantly enriched in biological processes related to steroid biosynthesis, ovarian follicle development, female gonad development, regulation of reproductive processes, apoptosis regulation, circadian rhythm, and associated signaling pathways. These findings suggest that MLT regulates ovarian germ cell development and estrogen synthesis signaling pathways through modulation of Ddx4, Ar, and Erα expression. - Source: PubMed
Publication date: 2026/07/02
Zhang FangdiMa RuixueJin YadanWang KaixuanHe HaiweiWang FeiZhang Guoliang - Ulcerative colitis (UC) is an inflammatory bowel disease driven by genetic, immune and environmental factors, among which macrophage infiltration is one of its core pathological features. Moreover, as an important bridge between oxidative stress and inflammation, ferroptosis, a nonapoptotic cell death mechanism, plays an increasingly prominent role in inflammatory diseases. However, whether ferroptosis occurs in colonic macrophages in UC mouse models and whether targeted intervention in this process can be effective for the treatment of UC remain to be elucidated. - Source: PubMed
Publication date: 2026/06/28
Xiong Wen-HaoHuang ShuoLiu Yan-HongChen Guo-ShanLi Dan-ZhouDi Yong-ChengSong Wen-BinZhang Yong-ChaoWang Yi-FanQi Feng - The persistence of the activation of pro-inflammatory cytokines, which facilitates the pathological tissue remodeling by disrupting the extracellular matrix (ECM), has been identified as a risk factor for chronic inflammation. A disproportion in the proinflammatory cytokines and anti-inflammatory cytokines enhances tissue destruction and disease etiology. - Source: PubMed
Publication date: 2026/03/31
Alyahya Wasman JaberAlbaghlany Rawayh Muslim - This study evaluated circulating mRNAs (B2M, TIMP-1, CLU, SERPINE1, GAL3, and S100A9) as potential biomarkers for colorectal cancer (CRC). Plasma levels were measured in CRC patients (stages I-IV, = 178) and healthy individuals (HIs, = 171). B2M, TIMP-1, CLU, and S100A9 mRNA levels were significantly elevated in CRC patients vs. HIs. B2M differed only in stage IV, while TIMP-1, CLU, and S100A9 showed significance across all stages except I. A composite index, I-BTC, was developed using B2M, TIMP-1, and CLU via logistic regression. I-BTC improved discrimination between HIs and CRC patients, even at stage I ( = 0.001), with stronger significance in later stages ( ≤ 0.0001). These results validate analytical robustness of the method and highlight its diagnostic potential including for early-stage CRC through specific mRNAs combinations. - Source: PubMed
Publication date: 2026/06/17
Mazard ThibaultGrosgeorges MarieVeyrie LauraThezenas SimonPastor BricePisareva EkaterinaLossaint GéraldLopez-Crapez EvelyneYchou MarcThierry Alain RPrévostel CorinneBlache Philippe